. Author manuscript; available in PMC: 2023 Aug 13.

Published in final edited form as: Sci Transl Med. 2022 Aug 24;14(659):eabn9709. doi: 10.1126/scitranslmed.abn9709

Table 2.

Detection of patency after CHMI.

CHMI	Statistic	Arm 1: 5×200 GAP3KO bites	Arm 2: 3×200 GAP3KO bites	CHMI infectivity controls

1	n/N^a	4/8	3/6	4/5

	Infection rate	0.50	0.50	0.80
	(95% CI)^b	(0.22, 0.78)	(0.19, 0.81)	(0.38, 0.96)

	Vaccine efficacy^c	0.38	0.38	N/A
	(95% CI)^d	(−0.75, 0.79)	(−1.13, 0.83)	N/A

2	n/N^a	¾	2/2	5/5

	Infection rate	0.75	1.00	1.00
	(95% CI)^b	(0.30, 0.95)	(0.34, 1.00)	(0.57, 1.00)

	Vaccine efficacy^c	0.25	0	N/A
	(95% CI)^d	(−0.57, 0.81)	0	N/A

n=number of subjects with malaria infection defined as a positive qRT-PCR assay with parasite density of ≥20 parasites/mL.

N=total number of subjects in the specified group who received the specified challenge.

Wilson score interval used for the confidence interval of the proportion.

Vaccine efficacy is defined as 1-pv/pc, where pv is the infection rate in the vaccinated group, and pc is the infection rate in the control group.

Confidence intervals for vaccine efficacy are calculated from exact unconditional confidence limits for relative risk based on the Farrington-Manning score statistic.

N/A=Not applicable.